| Characteristic |
White_Hisp, N = 11,809 |
White_Non-Hisp, N = 38,109 |
Black, N = 7,998 |
Chinese, N = 1,623 |
Japanese, N = 756 |
South_Asian, N = 1,089 |
Other_Asian, N = 4,787 |
Other, N = 1,575 |
| Nodes |
|
|
|
|
|
|
|
|
| Â Â Â Â N0 |
6,503 (55%) |
23,922 (63%) |
4,529 (57%) |
1,044 (64%) |
525 (69%) |
612 (56%) |
3,049 (64%) |
918 (58%) |
| Â Â Â Â N1 |
3,886 (33%) |
10,780 (28%) |
2,506 (31%) |
444 (27%) |
181 (24%) |
368 (34%) |
1,308 (27%) |
490 (31%) |
| Â Â Â Â N2 |
921 (7.8%) |
2,292 (6.0%) |
639 (8.0%) |
90 (5.5%) |
34 (4.5%) |
71 (6.5%) |
307 (6.4%) |
111 (7.0%) |
| Â Â Â Â N3 |
499 (4.2%) |
1,115 (2.9%) |
324 (4.1%) |
45 (2.8%) |
16 (2.1%) |
38 (3.5%) |
123 (2.6%) |
56 (3.6%) |
| Tumor size |
|
|
|
|
|
|
|
|
| Â Â Â Â T0 |
3 (<0.1%) |
4 (<0.1%) |
7 (<0.1%) |
1 (<0.1%) |
0 (0%) |
0 (0%) |
0 (0%) |
0 (0%) |
| Â Â Â Â T1 |
5,249 (44%) |
21,254 (56%) |
3,535 (44%) |
869 (54%) |
462 (61%) |
514 (47%) |
2,446 (51%) |
712 (45%) |
| Â Â Â Â T2 |
5,004 (42%) |
13,199 (35%) |
3,342 (42%) |
615 (38%) |
246 (33%) |
451 (41%) |
1,857 (39%) |
676 (43%) |
| Â Â Â Â T3 |
1,190 (10%) |
2,909 (7.6%) |
805 (10%) |
108 (6.7%) |
42 (5.6%) |
98 (9.0%) |
407 (8.5%) |
143 (9.1%) |
| Â Â Â Â T4 |
363 (3.1%) |
743 (1.9%) |
309 (3.9%) |
30 (1.8%) |
6 (0.8%) |
26 (2.4%) |
77 (1.6%) |
44 (2.8%) |
| Subtype |
|
|
|
|
|
|
|
|
| Â Â Â Â HR+/HER2- |
7,541 (64%) |
26,537 (70%) |
4,545 (57%) |
1,179 (73%) |
612 (81%) |
731 (67%) |
3,292 (69%) |
1,036 (66%) |
| Â Â Â Â HR+/HER2+ |
1,740 (15%) |
5,153 (14%) |
1,091 (14%) |
227 (14%) |
70 (9.3%) |
144 (13%) |
776 (16%) |
241 (15%) |
| Â Â Â Â HR-/HER2- |
1,875 (16%) |
4,800 (13%) |
1,894 (24%) |
141 (8.7%) |
55 (7.3%) |
156 (14%) |
417 (8.7%) |
181 (11%) |
| Â Â Â Â HR-/HER2+ |
653 (5.5%) |
1,619 (4.2%) |
468 (5.9%) |
76 (4.7%) |
19 (2.5%) |
58 (5.3%) |
302 (6.3%) |
117 (7.4%) |
| Grade |
|
|
|
|
|
|
|
|
| Â Â Â Â G1 |
1,689 (14%) |
7,387 (19%) |
856 (11%) |
301 (19%) |
185 (24%) |
159 (15%) |
806 (17%) |
269 (17%) |
| Â Â Â Â G2 |
4,756 (40%) |
16,406 (43%) |
2,663 (33%) |
742 (46%) |
341 (45%) |
476 (44%) |
2,100 (44%) |
642 (41%) |
| Â Â Â Â G3 |
5,364 (45%) |
14,316 (38%) |
4,479 (56%) |
580 (36%) |
230 (30%) |
454 (42%) |
1,881 (39%) |
664 (42%) |
| Stage (anatomical) |
|
|
|
|
|
|
|
|
| Â Â Â Â IA |
3,804 (32%) |
16,448 (43%) |
2,532 (32%) |
672 (41%) |
375 (50%) |
372 (34%) |
1,928 (40%) |
526 (33%) |
| Â Â Â Â IB |
275 (2.3%) |
1,084 (2.8%) |
182 (2.3%) |
43 (2.6%) |
27 (3.6%) |
25 (2.3%) |
108 (2.3%) |
29 (1.8%) |
| Â Â Â Â IIA |
3,314 (28%) |
9,675 (25%) |
2,350 (29%) |
467 (29%) |
191 (25%) |
314 (29%) |
1,333 (28%) |
473 (30%) |
| Â Â Â Â IIB |
2,259 (19%) |
5,707 (15%) |
1,448 (18%) |
239 (15%) |
93 (12%) |
213 (20%) |
754 (16%) |
291 (18%) |
| Â Â Â Â IIIA |
1,355 (11%) |
3,474 (9.1%) |
913 (11%) |
133 (8.2%) |
50 (6.6%) |
105 (9.6%) |
477 (10.0%) |
165 (10%) |
| Â Â Â Â IIIB |
303 (2.6%) |
606 (1.6%) |
249 (3.1%) |
24 (1.5%) |
4 (0.5%) |
22 (2.0%) |
64 (1.3%) |
35 (2.2%) |
| Â Â Â Â IIIC |
499 (4.2%) |
1,115 (2.9%) |
324 (4.1%) |
45 (2.8%) |
16 (2.1%) |
38 (3.5%) |
123 (2.6%) |
56 (3.6%) |
| Stage (prognostic) |
|
|
|
|
|
|
|
|
| Â Â Â Â IA |
3,533 (30%) |
15,582 (41%) |
2,138 (27%) |
665 (41%) |
378 (50%) |
346 (32%) |
1,876 (39%) |
505 (32%) |
| Â Â Â Â IB |
2,475 (21%) |
7,854 (21%) |
1,560 (20%) |
353 (22%) |
153 (20%) |
234 (21%) |
1,030 (22%) |
345 (22%) |
| Â Â Â Â IIA |
2,513 (21%) |
7,177 (19%) |
1,523 (19%) |
350 (22%) |
118 (16%) |
228 (21%) |
1,027 (21%) |
362 (23%) |
| Â Â Â Â IIB |
1,584 (13%) |
3,976 (10%) |
1,363 (17%) |
133 (8.2%) |
60 (7.9%) |
154 (14%) |
476 (9.9%) |
190 (12%) |
| Â Â Â Â IIIA |
258 (2.2%) |
537 (1.4%) |
191 (2.4%) |
18 (1.1%) |
10 (1.3%) |
21 (1.9%) |
73 (1.5%) |
29 (1.8%) |
| Â Â Â Â IIIB |
1,042 (8.8%) |
2,204 (5.8%) |
803 (10%) |
84 (5.2%) |
29 (3.8%) |
89 (8.2%) |
235 (4.9%) |
101 (6.4%) |
| Â Â Â Â IIIC |
404 (3.4%) |
779 (2.0%) |
420 (5.3%) |
20 (1.2%) |
8 (1.1%) |
17 (1.6%) |
70 (1.5%) |
43 (2.7%) |
| PAM cluster |
|
|
|
|
|
|
|
|
| Â Â Â Â subtype_1+ |
1,351 (11%) |
6,421 (17%) |
704 (8.8%) |
264 (16%) |
168 (22%) |
139 (13%) |
695 (15%) |
219 (14%) |
| Â Â Â Â subtype_1a |
2,036 (17%) |
8,129 (21%) |
1,150 (14%) |
386 (24%) |
212 (28%) |
210 (19%) |
1,083 (23%) |
280 (18%) |
| Â Â Â Â subtype_1b |
1,960 (17%) |
5,836 (15%) |
985 (12%) |
249 (15%) |
101 (13%) |
190 (17%) |
684 (14%) |
250 (16%) |
| Â Â Â Â subtype_1c |
1,002 (8.5%) |
3,237 (8.5%) |
873 (11%) |
164 (10%) |
72 (9.5%) |
93 (8.5%) |
440 (9.2%) |
151 (9.6%) |
| Â Â Â Â subtype_1d |
1,208 (10%) |
2,970 (7.8%) |
845 (11%) |
120 (7.4%) |
59 (7.8%) |
101 (9.3%) |
393 (8.2%) |
138 (8.8%) |
| Â Â Â Â subtype_2a |
746 (6.3%) |
2,663 (7.0%) |
488 (6.1%) |
104 (6.4%) |
40 (5.3%) |
61 (5.6%) |
373 (7.8%) |
96 (6.1%) |
| Â Â Â Â subtype_2b |
994 (8.4%) |
2,490 (6.5%) |
603 (7.5%) |
123 (7.6%) |
30 (4.0%) |
83 (7.6%) |
403 (8.4%) |
145 (9.2%) |
| Â Â Â Â subtype_3a |
1,091 (9.2%) |
3,088 (8.1%) |
1,103 (14%) |
87 (5.4%) |
35 (4.6%) |
89 (8.2%) |
261 (5.5%) |
108 (6.9%) |
| Â Â Â Â subtype_3b |
773 (6.5%) |
1,669 (4.4%) |
785 (9.8%) |
51 (3.1%) |
20 (2.6%) |
65 (6.0%) |
153 (3.2%) |
72 (4.6%) |
| Â Â Â Â subtype_4 |
648 (5.5%) |
1,606 (4.2%) |
462 (5.8%) |
75 (4.6%) |
19 (2.5%) |
58 (5.3%) |
302 (6.3%) |
116 (7.4%) |
| Age |
42.2 (5.6) |
43.1 (5.3) |
42.2 (5.7) |
43.1 (5.0) |
43.4 (4.9) |
41.5 (5.6) |
42.8 (5.0) |
42.3 (5.7) |
| Mortality status |
|
|
|
|
|
|
|
|
| Â Â Â Â 0 |
10,480 (89%) |
34,604 (91%) |
6,506 (81%) |
1,509 (93%) |
716 (95%) |
999 (92%) |
4,471 (93%) |
1,391 (88%) |
| Â Â Â Â 1 |
1,329 (11%) |
3,505 (9.2%) |
1,492 (19%) |
114 (7.0%) |
40 (5.3%) |
90 (8.3%) |
316 (6.6%) |
184 (12%) |
| Cause of death |
|
|
|
|
|
|
|
|
| Â Â Â Â Breast |
1,094 (82%) |
2,689 (77%) |
1,167 (78%) |
93 (82%) |
29 (73%) |
72 (80%) |
263 (83%) |
129 (70%) |
| Â Â Â Â CVD |
20 (1.5%) |
97 (2.8%) |
67 (4.5%) |
1 (0.9%) |
0 (0%) |
0 (0%) |
4 (1.3%) |
5 (2.7%) |
| Â Â Â Â Other |
215 (16%) |
719 (21%) |
258 (17%) |
20 (18%) |
11 (28%) |
18 (20%) |
49 (16%) |
50 (27%) |
| Â Â Â Â Unknown |
10,480 |
34,604 |
6,506 |
1,509 |
716 |
999 |
4,471 |
1,391 |
















